9.4 Vaccination & Travel Health

9.4 Vaccination & Travel Health

Quick Answer: Pharmacist immunisation is a state/territory-regulated advanced practice: confirm your legal scope, maintain cold chain, obtain informed consent, prepare for anaphylaxis, align with the National Immunisation Program and current ATAGI-aligned guidance, and counsel high-volume vaccines (influenza, COVID-19, pneumococcal, zoster) plus travel risks including malaria prophylaxis adherence. Communicate respectfully with hesitant patients using evidence and autonomy.

Vaccination sits at the intersection of Competency 3.6 (health promotion) and 3.1–3.3 (assessment, implementation, monitoring). The Intern Written Examination tests principles and safety systems more than memorising every brand name.

Pharmacist vaccination role in Australia (jurisdictional principles)

Australia does not have a single identical national pharmacist vaccination law for every antigen and age. Instead:

• Each state and territory defines which vaccines pharmacists may administer, under what training/certification, in which settings, and for which age groups
• National frameworks and programs (NIP funding, Australian Immunisation Handbook guidance, ATAGI statements) inform what is recommended, while local Drugs and Poisons / pharmacy legislation inform who may administer
• Intern pharmacists must know their supervised practice rules — observation, countersigning, and restrictions differ from fully registered pharmacist immunisers

Exam principle: When a scenario asks whether a pharmacist “can vaccinate,” the correct reasoning includes jurisdiction + training + vaccine type + patient age/eligibility, not a blanket yes/no for all of Australia.

Community roles beyond injection:

• Opportunistic recommendation and booking
• Screening for contraindications and precautions
• Cold chain receiving and storage
• Documentation and immunisation register reporting pathways used locally
• Post-vaccination observation and adverse event advice
• Referral when complex medical history exceeds pharmacist protocol

Cold chain

Vaccines are biological products: potency fails if temperatures breach recommended ranges (commonly +2 °C to +8 °C for many refrigerated vaccines — always follow product and handbook requirements; some have frozen storage or special conditions).

Cold chain essentials:

If cold chain fails, isolate stock, document, contact manufacturer/public health advice pathways as required, and do not administer compromised vaccines. Intern scenarios reward quarantine + escalate, not “use it anyway because the patient is waiting.”

Informed consent

Consent must be voluntary, informed, and capacity-based (parent/guardian for children per local rules). Provide in plain language:

• Disease risk being prevented
• Vaccine benefits and common adverse effects (local soreness, low-grade fever, fatigue)
• Rare serious risks (including anaphylaxis)
• Alternatives (including declining)
• Opportunity for questions

Screen before vaccination: allergies to vaccine components (e.g. prior anaphylaxis to a component), acute severe febrile illness (deferral decisions), pregnancy considerations for live vaccines, immunosuppression for live vaccines, and recent other vaccines when spacing rules apply. Document consent and batch details per protocol.

Anaphylaxis preparedness

Every immunisation setting needs:

1. Immediate access to adrenaline (epinephrine) in correct strengths/devices per protocol
2. Trained staff who can recognise anaphylaxis (respiratory compromise, hypotension, urticaria/angioedema, collapse)
3. Emergency response plan and ability to call ambulance
4. Post-vaccination observation period (commonly around 15 minutes; longer if higher risk)
5. Incident documentation and adverse event reporting pathways (including TGA/state systems as applicable)

Mild vasovagal syncope is not anaphylaxis — but you must differentiate. Lay the patient flat if faint; for anaphylaxis follow adrenaline-first emergency algorithms. Do not administer vaccines in settings without emergency readiness.

National Immunisation Program (NIP) awareness

The NIP funds scheduled vaccines for eligible groups across the life course (infants, children, adolescents, pregnancy programs, older adults, and risk groups). Exact funded products and ages update — use current NIP schedule and Handbook for detail.

Pharmacist value:

• Identify people overdue for funded vaccines
• Explain eligibility (age, Aboriginal and Torres Strait Islander status, medical risk conditions, pregnancy)
• Support catch-up schedules without unnecessary restarts when valid doses exist
• Direct people to GPs/clinics when the required vaccine is outside pharmacist scope or needs medical assessment

Australian Immunisation Register (AIR) recording supports continuity and school/work evidence where required.

High-volume adult vaccine concepts

Influenza

Annual influenza vaccination is recommended for broad groups, with strong emphasis on older adults, pregnant people, young children in schedule groups, Aboriginal and Torres Strait Islander peoples, and those with chronic disease. Counsel: vaccines do not cause influenza disease from inactivated products used in standard programs; protection is partial but reduces severe outcomes; best given before the season peaks but still useful when circulating. Egg allergy pathways have modernised — follow current Handbook (severe anaphylaxis history still needs specialist pathways).

COVID-19

Recommendations evolve with epidemiology and ATAGI updates (primary courses, boosters, risk-group prioritisation, pregnancy guidance). Pharmacists must use current advice rather than outdated 2021 talking points. Counsel expected reactogenicity, rare serious adverse events in context of disease risk, and co-administration rules when allowed.

Pneumococcal

Pneumococcal vaccines protect against invasive disease and pneumonia risk groups (older adults, immunocompromised, chronic disease, some Indigenous populations with specific schedules). Product choice (conjugate vs polysaccharide pathways) and spacing are schedule-specific — verify Handbook rather than improvising brand swaps.

Zoster (shingles)

Recombinant zoster vaccine programs for older adults (and some immunocompromised groups under evolving rules) reduce shingles and post-herpetic neuralgia risk. Counsel two-dose completion when a multi-dose course is indicated, expected local/systemic reactogenicity, and that prior shingles does not always remove benefit of vaccination after recovery (timing per guidance).

Travel vaccines and malaria chemoprophylaxis (high-level)

Travel consults start with destination, itinerary, duration, season, activities (rural, medical work), pregnancy, immunosuppression, and routine schedule status. Not every traveller needs every exotic vaccine.

Common travel-related immunisations (examples of categories, not a complete prescription list):

• Hepatitis A, typhoid for many food/water risk itineraries
• Hepatitis B if not immune and risk of blood/sexual exposure
• Rabies pre-exposure for selected high-risk travel
• Japanese encephalitis, yellow fever, meningococcal for specific regions/activities
• Cholera rarely for standard tourists

Yellow fever has international certificate requirements for some borders — timing matters.

Malaria chemoprophylaxis counselling

For malaria-risk regions, prevention is bite avoidance + chemoprophylaxis when indicated + urgent fever assessment after return.

High-level agent classes (selection is medical/itinerary-specific):

• Atovaquone–proguanil — daily; start before arrival, continue after leaving risk area per product timing; well tolerated for many short trips; cost considerations
• Doxycycline — daily; photosensitivity and oesophagitis counselling; continue after leaving risk area; not for pregnancy/young children when alternatives exist
• Mefloquine — weekly regimens in some pathways; neuropsychiatric adverse effect screening and contraindications critical

Adherence counselling is the intervention: missing doses collapses protection. Explain start/stop windows relative to travel dates, take with food if required, and that prophylaxis is not 100% — fever during/after travel is an emergency medical review, mentioning travel history.

Standby emergency treatment concepts exist in specialist advice for selected travellers — not casual OTC improvisation.

Vaccine hesitancy — respectful communication

Hesitancy is common and multi-causal (safety fears, mistrust, access, misinformation, cultural factors). Effective pharmacist communication:

1. Listen without ridicule — ask what specifically worries them
2. Acknowledge emotions and prior experiences
3. Share clear evidence on benefits and known risks in proportion
4. Correct specific myths gently with Handbook-aligned facts
5. Support autonomy — informed adults can decline; keep the door open
6. Avoid coercive shaming that destroys therapeutic relationship
7. For parents, focus on protecting the child and community, and offer reliable resources

Motivational interviewing style beats argument. Document discussions and offer follow-up.

Adverse events and reporting

Explain common self-limiting reactions and when to seek care (high fever, extensive swelling, dyspnoea, urticaria, neurological symptoms). Serious events need medical care and formal reporting. Pharmacists contribute to vaccine safety surveillance by reporting suspected adverse events following immunisation.

Exam mindset

Intern Written vaccination items reward jurisdictional humility, cold chain discipline, consent quality, anaphylaxis readiness, NIP eligibility thinking, accurate adult vaccine counselling, travel risk assessment logic, malaria adherence, and respectful hesitancy communication. When schedules change, principles remain: right patient, right vaccine, right storage, right consent, right emergency plan.